ArticleCancer medicine2019
Severe muscle loss during radical chemoradiotherapy for non-metastatic nasopharyngeal carcinoma predicts poor survival.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.Annals of medicine · 2025Pooled it
- The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysis.British journal of cancer · 2025Pooled it
- Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Sarcopenia Is a Prognostic Factor of Adverse Effects and Mortality in Patients With Tumour: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- The effect of quantitative goal exercise combined with whole process refined nutrition management on the nutritional status and quality of life of head and neck cancer patients undergoing radiotherapy: an open-label, randomized, controlled trial.Radiation oncology (London, England) · 2026Trial
- Developing a supportive care pathway for sarcopenia prevention in nasopharyngeal carcinoma: a context-sensitive and implementation-oriented approach.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Impact of magnetic resonance imaging-derived skeletal muscle index in locoregionally advanced nasopharyngeal carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- The Use of Pre-Chemoradiotherapy Total Masseter Muscle Volume as a Novel Predictor of Radiation-Induced Trismus in Locally Advanced Nasopharyngeal Carcinoma Patients.Tomography (Ann Arbor, Mich.) · 2024Article
- Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy.Journal of clinical medicine · 2023Article
- Chemotherapy-Induced Molecular Changes in Skeletal Muscle.Biomedicines · 2023Review
- Linear Skeletal Muscle Index and Muscle Attenuation May Be New Prognostic Factors in Colorectal Carcinoma Treated by Radical Resection.Frontiers in oncology · 2022Article
- Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention.Frontiers in oncology · 2022Article
- Article
- Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy.Journal of clinical medicine · 2021Article
- Optimal Skeletal Muscle Mass Index Cut-Off Values for Presarcopenia Evaluated by Computed Tomography against Dual-Energy X-ray Absorptiometry in Patients with Chronic Liver Disease.Journal of clinical medicine · 2021Article
- Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis.Therapeutic advances in medical oncology · 2021Article
- A Model Combining Skeletal Muscle Mass and a Hematological Biomarker to Predict Survival in Patients With Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy.Frontiers in oncology · 2021Article
- Body Composition Parameters May Be Prognostic Factors in Upper Urinary Tract Urothelial Carcinoma Treated by Radical Nephroureterectomy.Frontiers in oncology · 2021Article
- Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSkeletal muscle loss is a novel imaging biomarker that is considered to be predictive of survival outcomes and toxicity in a variety of solid tumors. This study explored to investigate whether skeletal muscle loss after chemoradiotherapy (CRT) in nasopharyngeal carcinoma (NPC) patients can predict survival.
methodsA total of 394 non-metastatic NPC patients were enrolled. The cross-sectional area of the third lumbar skeletal muscle based on computed tomography (CT) scan was measured and the skeletal muscle index (SMI) was calculated. A cut-off value suitable for the Chinese population was used to define sarcopenia, and relative changes in skeletal muscle after treatment were analyzed for the confirmation of skeletal muscle tissue loss during treatment and its impact on overall survival (OS).
resultsThe median follow-up was 22.7 (range, 2.5-46.4) months. One hundred and thirty patients (33.0%) were defined sarcopenia at baseline. Two hundred and forty one patients (61.2%) had posttreatment sarcopenia. The mean SMI before and after treatment was 42.8 and 38.1 cm
conclusionsDuring CRT, patients with NPC often experience different levels of muscle loss, and severe skeletal muscle loss may shorten OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.